- The impact of the new UK clinical trial regulations coming into force in April 2026 and what they mean for sponsors, investigators, and trial delivery
- Government priorities and progress across the UK clinical research ecosystem two years on
- How artificial intelligence is transforming clinical trial design, feasibility, patient identification, and operational efficiency
- Cross-sector collaboration between regulators, industry, and the NHS to strengthen the UK’s position as a leading destination for clinical research
- Looking ahead: building a more agile, technology-enabled clinical trials environment in the UK
Archives: Agenda
Registration and Refreshments
PANEL DISCUSSION Harnessing Real-World Data and Registries in Clinical Trials: UK & Ireland Perspectives
- Overview of available RWD sources and disease registries across the UK and Ireland, and how they can support trial design.
- Leveraging RWD to inform patient eligibility, site selection, and endpoint development.
- Practical considerations for integrating registry data with trial datasets while ensuring data quality and regulatory compliance.
- Case studies demonstrating how RWD and registries have accelerated clinical trial insights and improved patient outcomes.
PANEL DISCUSSION From Transactional Outsourcing to Strategic Partnership: Aligning Incentives, Expectations, and Execution in Clinical Trials
- Planning for successful sponsor–vendor relationships
- Common challenges and pitfalls with vendors and how to address them
- Improving transparency and alignment across multi-partner trial ecosystems
- What effective strategic partnership looks like in practice
SPOTLIGHT – Innovation in Rare Disease
|
FIRESIDE CHAT Risks & Controversies of AI in Clinical Trials
- Automation bias in practice: Real-world cases show dosing errors occurring when clinicians rely on AI outputs without independent verification.
- Human oversight failures: Over-reliance on AI, combined with missed pharmacist checks, can directly compromise patient safety.
- Cognitive deskilling risk: Persistent dependence on AI may erode critical thinking, clinical judgement, and professional expertise over time.
- Long-term human impact: Growing concern that excessive cognitive offloading to AI could contribute to reduced mental resilience and potential long-term cognitive health risks, highlighting the need for balanced human – AI interaction.
Afternoon refreshments, networking & Apple prize draw
From Friction to Flow: The Future of Imaging in Clinical Trials
- Automation from scan to endpoint
- Imaging biomarkers and expert readers
- Site connectivity for full traceability
Regulatory landscape for AI & Software in UK & Ireland
| A concise overview of how AI and software-based medical technologies are regulated across England and Ireland, highlighting alignment, divergence, and what developers and trial teams need to plan for now. |